SK281324B6 - Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky - Google Patents

Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky Download PDF

Info

Publication number: SK281324B6
Authority: SK; Slovakia
Prior art keywords: vaccine; polypeptide; streptococcus suis; hemolysin; vac
Prior art date: 1993-05-17

Application number

SK563-94A

Other languages

English (en)

Slovak (sk)

Other versions

SK56394A3 (en

Inventor

Antonius Arnoldus Christiaan Jacobs

Original Assignee

Akzo Nobel N. V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-17

Filing date

1994-05-13

Publication date

2001-02-12

1994-05-13 Application filed by Akzo Nobel N. V. filed Critical Akzo Nobel N. V.

1995-07-11 Publication of SK56394A3 publication Critical patent/SK56394A3/sk

2001-02-12 Publication of SK281324B6 publication Critical patent/SK281324B6/sk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 74
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 59
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 58
229920001184 polypeptide Polymers 0.000 title claims abstract description 57
238000004519 manufacturing process Methods 0.000 title abstract description 5
238000000034 method Methods 0.000 title description 11
241000894006 Bacteria Species 0.000 title description 7
230000008569 process Effects 0.000 title description 2
241000194021 Streptococcus suis Species 0.000 claims abstract description 40
206010061372 Streptococcal infection Diseases 0.000 claims abstract description 8
230000002949 hemolytic effect Effects 0.000 claims description 41
241000282887 Suidae Species 0.000 claims description 31
230000002163 immunogen Effects 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 7
150000004676 glycans Chemical class 0.000 claims description 6
229920001282 polysaccharide Polymers 0.000 claims description 6
239000005017 polysaccharide Substances 0.000 claims description 6
230000028993 immune response Effects 0.000 claims description 5
125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
230000003472 neutralizing effect Effects 0.000 abstract 1
239000003228 hemolysin Substances 0.000 description 55
108010006464 Hemolysin Proteins Proteins 0.000 description 50
108090000623 proteins and genes Proteins 0.000 description 38
235000018102 proteins Nutrition 0.000 description 37
102000004169 proteins and genes Human genes 0.000 description 37
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
210000002966 serum Anatomy 0.000 description 26
239000012228 culture supernatant Substances 0.000 description 25
241000699670 Mus sp. Species 0.000 description 24
239000000427 antigen Substances 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
230000000694 effects Effects 0.000 description 16
241000700605 Viruses Species 0.000 description 15
235000012000 cholesterol Nutrition 0.000 description 15
239000000243 solution Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
229940068196 placebo Drugs 0.000 description 14
239000000902 placebo Substances 0.000 description 14
238000003119 immunoblot Methods 0.000 description 13
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
241000282898 Sus scrofa Species 0.000 description 12
238000003556 assay Methods 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
230000001717 pathogenic effect Effects 0.000 description 9
238000002255 vaccination Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000000523 sample Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
238000005119 centrifugation Methods 0.000 description 6
238000011282 treatment Methods 0.000 description 6
201000009906 Meningitis Diseases 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000027455 binding Effects 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000002372 labelling Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
241000588722 Escherichia Species 0.000 description 4
206010018910 Haemolysis Diseases 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229940030156 cell vaccine Drugs 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000008588 hemolysis Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
210000001503 joint Anatomy 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
150000003573 thiols Chemical class 0.000 description 4
239000003053 toxin Substances 0.000 description 4
231100000765 toxin Toxicity 0.000 description 4
108700012359 toxins Proteins 0.000 description 4
230000007923 virulence factor Effects 0.000 description 4
239000000304 virulence factor Substances 0.000 description 4
108010067770 Endopeptidase K Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
239000000969 carrier Substances 0.000 description 3
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
230000001018 virulence Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
238000011537 Coomassie blue staining Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108050001049 Extracellular proteins Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
206010060860 Neurological symptom Diseases 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
206010036030 Polyarthritis Diseases 0.000 description 2
241000702670 Rotavirus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000002224 dissection Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
208000030428 polyarticular arthritis Diseases 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
208000009305 pseudorabies Diseases 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
201000010740 swine influenza Diseases 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
241000606750 Actinobacillus Species 0.000 description 1
241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 1
VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
-1 Bayol R or Markol R Substances 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241001023795 Brochis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101710179002 Hemolytic toxin Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241000606856 Pasteurella multocida Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010036141 Polyserositis Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000028990 Skin injury Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000021310 complex sugar Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
102220069296 rs200203042 Human genes 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000029305 taxis Effects 0.000 description 1
239000007078 todd-hewitt medium Substances 0.000 description 1
230000024033 toxin binding Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000013598 vector Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SK563-94A 1993-05-17 1994-05-13 Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky SK281324B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP93201401		1993-05-17

Publications (2)

Publication Number	Publication Date
SK56394A3 SK56394A3 (en)	1995-07-11
SK281324B6 true SK281324B6 (sk)	2001-02-12

Family

ID=8213828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK563-94A SK281324B6 (sk)	1993-05-17	1994-05-13	Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky

Country Status (13)

Country	Link
US (1)	US5612042A (fr)
EP (1)	EP0626452B1 (fr)
JP (1)	JP3578799B2 (fr)
AT (1)	ATE183241T1 (fr)
CZ (1)	CZ289302B6 (fr)
DE (1)	DE69419966T2 (fr)
DK (1)	DK0626452T3 (fr)
ES (1)	ES2137310T3 (fr)
GR (1)	GR3031698T3 (fr)
HU (1)	HU218154B (fr)
PL (1)	PL177219B1 (fr)
SK (1)	SK281324B6 (fr)
TW (1)	TW494103B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI93733C (fi) *	1993-01-29	1995-05-26	Kaarina Tikkanen	Streptococcus suis-bakteerin adhesiiniproteiini ja menetelmä sen valmistamiseksi
US5919466A (en) *	1993-10-01	1999-07-06	Gerbu Biotechnik Gmbh	Method for improving the yield of immunoantibodies in the vaccination of animals and humans
US6936259B2 (en)	1995-06-08	2005-08-30	University Of Saskatchewan	CAMP factor of Streptococcus uberis
CA2222701C (fr)	1995-06-08	2012-02-07	University Of Saskatchewan	Facteur camp du streptococcus uberis
US5863543A (en) *	1996-06-05	1999-01-26	University Of Saskatchewan	Camp factor of streptococcus uberis
ZA97452B (en) *	1996-01-25	1997-08-15	Trinity College Dublin	Streptococcus equi vaccine.
AU769539B2 (en)	1999-01-29	2004-01-29	Zoetis Services Llc	Adjuvants for use in vaccines
FR2791895B1 (fr) *	1999-03-23	2001-06-15	Pasteur Merieux Serums Vacc	Utilisation de trehalose pour stabiliser un vaccin liquide
DK1328543T3 (da) *	2000-10-27	2009-11-23	Novartis Vaccines & Diagnostic	Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
NO318426B1 (no)	2001-10-02	2005-04-18	Neurozym Biotech As	Et materiale for a senke konsentrasjonen av patogene tarmpeptider
DE10239629A1 (de) *	2002-08-23	2004-04-08	Idt Impfstoffwerk Dessau-Tornau Gmbh	Nicht-rekombinate Subunit-Vakzine gegen Streptococcus suis-Infektionen des Schweines
AU2007245198B2 (en) *	2006-03-30	2010-08-12	Zoetis Services Llc	Methods and compositions for vaccination of poultry
US7572457B2 (en) *	2006-03-31	2009-08-11	Wisconsin Alumni Research Foundation	Use of Streptococcus suis 38 kDa polypeptide as an immunogen
JP5339243B2 (ja) *	2008-04-24	2013-11-13	株式会社微生物化学研究所	ストレプトコッカス・スイス感染症予防用ワクチン
TW201043242A (en) *	2009-03-26	2010-12-16	Intervet Int Bv	Vaccine for protection against Streptococcus suis bacteria of various serotypes
EP3319630A1 (fr)	2015-07-09	2018-05-16	Intervacc AB	Vaccin contre une infection à s.suis
US20180271969A1 (en) *	2015-10-07	2018-09-27	Boehringer Ingelheim Vetmedica, Inc.	Streptococcus suis polysaccharide-protein conjugate composition
GB201703529D0 (en) *	2017-03-06	2017-04-19	Cambridge Entpr Ltd	Vaccine composition
CN113957057B (zh) *	2021-11-16	2023-10-20	西南大学	一种杂交瘤细胞、能中和猪溶素的单克隆抗体及检测试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5059419A (en) *	1988-06-09	1991-10-22	Grand Laboratories, Inc.	Streptococcus suis antiserum and its use in treating Streptococcus suis infections

1994
- 1994-05-09 ES ES94201295T patent/ES2137310T3/es not_active Expired - Lifetime
- 1994-05-09 EP EP94201295A patent/EP0626452B1/fr not_active Expired - Lifetime
- 1994-05-09 DK DK94201295T patent/DK0626452T3/da active
- 1994-05-09 DE DE69419966T patent/DE69419966T2/de not_active Expired - Fee Related
- 1994-05-09 AT AT94201295T patent/ATE183241T1/de not_active IP Right Cessation
- 1994-05-13 SK SK563-94A patent/SK281324B6/sk unknown
- 1994-05-13 US US08/242,406 patent/US5612042A/en not_active Expired - Fee Related
- 1994-05-13 TW TW083104343A patent/TW494103B/zh not_active IP Right Cessation
- 1994-05-13 CZ CZ19941175A patent/CZ289302B6/cs not_active IP Right Cessation
- 1994-05-16 HU HU9401511A patent/HU218154B/hu not_active IP Right Cessation
- 1994-05-16 PL PL94303482A patent/PL177219B1/pl not_active IP Right Cessation
- 1994-05-17 JP JP10308094A patent/JP3578799B2/ja not_active Expired - Fee Related
1999
- 1999-11-03 GR GR990402789T patent/GR3031698T3/el unknown

Also Published As

Publication number	Publication date
EP0626452A1 (fr)	1994-11-30
PL177219B1 (pl)	1999-10-29
DE69419966D1 (de)	1999-09-16
TW494103B (en)	2002-07-11
GR3031698T3 (en)	2000-02-29
JP3578799B2 (ja)	2004-10-20
US5612042A (en)	1997-03-18
HU9401511D0 (en)	1994-08-29
ES2137310T3 (es)	1999-12-16
DE69419966T2 (de)	2000-01-20
CZ117594A3 (en)	1995-02-15
EP0626452B1 (fr)	1999-08-11
DK0626452T3 (da)	2000-02-14
ATE183241T1 (de)	1999-08-15
JPH0710774A (ja)	1995-01-13
CZ289302B6 (cs)	2001-12-12
HU218154B (hu)	2000-06-28
SK56394A3 (en)	1995-07-11
PL303482A1 (en)	1994-12-12
HUT69796A (en)	1995-09-28

Publication	Publication Date	Title
SK281324B6 (sk)	2001-02-12	Polypeptid zo streptococcus suis, vakcína, spôsob výroby vakcíny a protilátky
Von Specht et al.	1995	Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins
CZ284538B6 (cs)	1998-12-16	Očkovací látka proti boreliose, způsob její výroby a monoklonální protilátky
EP0656014B1 (fr)	2003-05-14	Proteine de surface cellulaire appelee proteine rib qui immunise contre plusieurs souches de streptocoques du groupe b; procede de purification de la proteine rib, trousse de reactifs et composition pharmaceutique
US10261092B2 (en)	2019-04-16	Cross-reactive determinants and methods for their identification
US5369019A (en)	1994-11-29	Pasteurella vaccine
US5885589A (en)	1999-03-23	Pasteurella vaccine
AU681130C (en)	1998-09-24	Protein rib, a cell surface protein that confers immunity tomany strains of the group B streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
KR0180991B1 (ko)	1999-04-01	합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
DK169749B1 (da)	1995-02-13	DNA-fragment, der koder for et Pasteurella multocida-toxin eller for en immunogen subsekvens eller analog deraf, ekspressionsvektor, der omfatter DNA-fragmentet, fremgangsmåde til fremstilling af et Pasteurella multocida-toxin og anvendelse af Pasteurella multocida-toxinsekvens eller -analog til fremstilling af en vaccine
Tsang et al.	1983	Antigenic analysis of Barber's protein antigen prepared from Salmonella typhi and demonstration of protein-specific antibodies in sera of typhoid patients
HK1149770B (en)	2016-02-19	Compositions, methods and kits
Moore	1991	crja4/^ Yf _
HK1008825B (en)	2004-01-16	Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition